Skip to main content
Clinical Trials/NL-OMON34838
NL-OMON34838
Recruiting
Not Applicable

Pilot study: clinical evaluation of biomarkers as predictors of survival in castrate-resistant prostate cancer patients. - BOSS - Biomarker Overall Survival Study in CRPC patients

niversitair Medisch Centrum Sint Radboud0 sites50 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
niversitair Medisch Centrum Sint Radboud
Enrollment
50
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational non invasive

Investigators

Sponsor
niversitair Medisch Centrum Sint Radboud

Eligibility Criteria

Inclusion Criteria

  • 1\. Histologically confirmed prostate cancer
  • 2\. Either biological recurrence (2 consecutive increases in the PSA level after the nadir, with a
  • minimum 2 week interval between measurements) and/or radiological recurrence (new
  • osseous lesions and/or new or enlarged soft tissue metastases)
  • 3\. Testosterone \<50 ng/mL
  • 4\. PSA \>5 ng/mL
  • 5\. ECOG performance status of 0\-2
  • 6\. Starting first course docetaxel\-based chemotherapy treatment

Exclusion Criteria

  • Within 4 wk of entry use of an antiandrogen (6wk for nilutamide and bicalutamide).
  • Within 30 days of entry radiation or radionuclide therapy.

Outcomes

Primary Outcomes

Not specified

Similar Trials